paziente avrebbe potuto beneficiare di un cambiamento di schema
terapeutico.
64
Bibliografia
1
Bonadonna G. In: Bonadonna G, Robustelli della Cuna G, Valagussa P: Medicina Oncologica, Ottava Edizione. Elsevier Masson, Milano, 2007
2
Wagner HN, Wiseman GA, Marcus CS, et al: Administration Guidelines for Radioimmunotherapy of Non-Hodgkin’s Lymphoma with 90Y-Labeled Anti-CD20 Monoclonal Antibody. J Nucl Med 43:267-272, 2002
3
Hangenbeek A, Lewington V: Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 16:786-792, 2005
4
Grillo-Lopez A, Chinn P, Morena R, et al. Treatment of relapsed non Hodgkin’s lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT). Ann Oncol 7 (Suppl): 57, abstract 195. 1996
5
Wiseman G, White C, Witzig T, et al. Radioimmunotherapy of relapsed non- Hodgkin’s lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5(Suppl): 3281s-3286s, 1999
6
Witzig T, White C, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non- Hodgkin’s lymphoma. J Clin Oncol 17: 3793-3803, 1999
7
Witzig T, Gordon L, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular lymphoma, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453-2463, 2002
8
Wiseman G, Gordon L, Multani P, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s lymphoma and mild thrombocytopenia- a phase II multicenter trial. Blood 99: 4336-4342, 2002
9
Witzig T, Flinn I, Gordon L, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non- Hodgkin’s lymphoma. J Clin Oncol 20: 3262-3269, 2002
10
Fanti S, Franchi R, Battista G, et al: PET e PET-TC. Stato dell’arte e prospettive future. Radiol Med 110: 1-15, 2005
11
Phelps ME: Positron emission tomography provides molecular imaging of biological processes. PNAS 97:9226-9233, 2000
65
12
Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42 (Suppl): 1S-93S, 2001
13
G. Jerusalem, Y. Beguin, M.F. Fassotte, F. Najjar, P. Paulus, P. Rigo, and G. Fillet. Whole-Body Positron Emission Tomography Using 18F- Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin's Disease and Non-Hodgkin's Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging. Blood, Jul 1999; 94: 429 - 433.
14
Costa DC, Visvikis D, Crosdale I, et al: Positron emission and computed X- ray tomography: a coming together . Nucl Med Commun 24: 351-358, 2003
15
Townsend DW,. Beyer T: A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75: S24-S30, 2002
16
Czernin Y: Editor-PET/CT: Imaging function and structure. J Nucl Med 45 (Suppl): 1S-103S, 2004
17
Freundenberg LS, Abtoch G, Schutt P, et al. FDG-PET/CT in re-staging patient with lymphoma. Eur j Nucl Med Mol Imaging 2004; 31: 325-9.
18
Beatriz Rodríguez-Vigil, Nieves Gómez-León, Inmaculada Pinilla, Dolores Hernández-Maraver, Juan Coya, Luis Martín-Curto, and Rosario Madero. PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT. J Nucl Med 47: 1643-1648.
19
M. Bangerter, F. Moog, I. Buchmann, J. Kotzerke, M. Griesshammer, M. Hafner, K. Elsner, N. Frickhofen, S. N. Reske, and L. Bergmann Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease Ann. Onc., October 1998; 9: 1117 - 1122.
20
Robert Carr, Sally F. Barrington, Bella Madan, Michael J. O'Doherty, Catherine A.B. Saunders, Jon van der Walt, and Adrian R. Timothy Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography
Blood, May1998; 91: 3340 - 3346.
21
Emilios E. Pakos, Andreas D. Fotopoulos, and John P.A. Ioannidis. 18F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: A Meta- Analysis. J Nucl Med 46: 958-963.
22
Jerusalem G. Warland V. Najjar F. et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin disease and non-Hodgkin lymphoma. Nucl Med Commun 1999; 20: 13-20.
23
Buchmann I. Reinhardt M. Elsner K. et al. 2-(fluorine-18)fluoro-2-deoxy-D- glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889-99.
66
24
Bruce D. Cheson, Sandra J. Horning, B. Coiffier, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.
J Clin Oncol Apr 1 1999: 1244.
25
F.A. Hampson, A.S. Shaw. Review: Response assessment in lymphoma. Clinical Radiology 2008 63, 125-135
26
Bruce D. Cheson, MD. The International Harmonization Project for Response Criteria in lymphoma clinical trials. Hemat/Oncol clin North America 2007; 21: 841-854
27
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, et al. Revised Response Criteria for Malignant Lymphoma. JCO Feb 10 2007: 579-586.
28
Callen PW, Korobkin M, Isherwood I. Computer Tomography evaluation of the retrocrural preverterbral space. AJR Am J Roentegnol 1977; 129: 907-10
29
Carrington B. Lymph nodes. In: Husband JES, Reznek RH, editors, Imaging in oncology, Vol. 2. 1998, p. 729-48.
30
Brodeur GM, Pritchard J, Berthold F, et al. Revision of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11: 1466-77.
31
Fuks JZ, Aisner J, Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin’s lymphoma. Med Pediatr Oncol 1982; 10: 429-38.
32
Stewart FM, Williamson BR, Innes DJ, et al. residual abdominal masses following treatment for advanced histiocytic lymphoma. Cancer 1985; 55: 620-3.
33
Surbone A, Longo DL, DeVita Jr VT, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemoterapy: significante and management. J Clin Oncol 1988; 6: 1832-7.
34
Coiffer B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen: a multicentre study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-26.
35
Niklaus G. Schaefer, Thomas F. Hany, Christian Taverna, et al. Non- Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restaging—Do We Need Contrast-enhanced CT? Radiology 2004 232: 823-829.
36
Juweid M, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 2005; 23: 4652-61.
67
37
Pfistner B, Diehl V, Cheson B. International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl 2005; 66: 53-4.
38
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in lymphoma. J Clin Oncol 2007; 25: 571-8.
39
Cheson BD, Pfistner B, Juweid ME, et al: Recommendations for revised response criteria for malignant lymphomas. J Clin Oncol 24: 423S, 2006 (suppl; abstr 7507)
40
Elstrom R, Guan L, Baker G, et al: Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101: 3875-3876, 2003
41
Schöder H, Noy A, Gönen M, et al: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23: 4643-4651, 2005
42
Juweid ME, Cheson BD: Role of positron emission tomography in lymphoma. J Clin Oncol 23: 4577-4580, 2005
43
Juweid ME, Cheson BD: Positron emission tomography and assessment of cancer theraphy. N Engl J Med 354: 496-507, 2006
44
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first line chemotherapy in non-Hodgkin lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
45
Spaepen K, Stroobants S, Dupont P, et al: Early staging positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose ( [18F]FDG) predicts outcome in patients with aggressive non Hodgkin’s lymphoma. Blood 2001; 98:726a.
46
Corinne Haioun, Emmanuel Itti, Alain Rahmouni, Pauline Brice, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, Aug 2005; 106: 1376 - 1381.
47
A Gallamini, L Rigacci, F Merli, L Nassi, A Bosi, I Capodanno, S Luminari, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 2006 Apr; 91: 475 - 481.
48
Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018-1027, 2002
68
49
Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol 2006; 17: 1296-1300.
50
Martin Hutchings, Annika Loft, Mads Hansen, Lars Møller Pedersen, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, Jan 2006; 107: 52 - 59.
51
Römer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in in non-Hodgkin’s lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
52
Zijlstra JM, van der Werf GL, Hoekstra OS, et al: 18F-fluoro-deoxyglucose positron emission tomography for post treatment evaluation of malignant lymphoma: A systematic review. Haematologica 91: 522-529, 2006
53
de Wit M, Bumann D, Beyer W, et al: Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8: 57-60, 1997
54
Naumann R, Vaic A, Beuthien-Baumann B, et al: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 115: 793-800, 2001
55
Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6: 931-933, 1988
56
Fanti S, Farsad M: La PET nell’iter diagnostico e terapeutico dei linfomi maligni. Seminari di Ematologia Oncologica 3: 191-205, 2006
57
Maisey NR, Hill ME, Webb A, et al: Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 36:200-206, 2000
58
Hoppe RT, Advani RH, Bierman PJ, et al. Hodjkin disease/lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4(3): 210-30.
59
Zelenetz AD, Advani RH, Buadi F, et al. Non-Hodgkin’s lymphoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4(3): 258-310.
60
Olsen K, Sohi J, Abraham T, et al: Initial validation of standardized qualitative (visual) criteria for FDG-PET assessment of residual masses following lymphoma therapy. Radiological Society of North America 92nd Scientific Assembly and Annual Meeting Program, 2006, pp 323 (abstr 55:E23- 02)
69
61
Sugawara Y, Zasadny KR, Kison PV, et al : Splenic fluorodeoxyglucose uptake increased by granulocyte-colony stimulating factor therapy: PET imaging results. J Nucl Med 40: 1456-1462, 1999
62
Freudenberg LS, Antoch G, Scütt P, et al: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31: 325-329, 2004
63
Spaepen K, Stroobants S, Dupont P, et al: [18F]FDG-PET monitoring of tumour response to chemotherapy: Does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30: 682-688, 2003
64
Lale Kostakoglu and Stanley J. Goldsmith. 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma. J Nucl Med 2003; 44: 224-239.